Packaging the Alkaloids of Cinchona Bark in Combination with Etoposide in Polymeric Micelles Nanoparticles

Today, cancer remains one of the major diseases that lead to death. The main obstacle in chemotherapy as a main cancer treatment is the toxicity to normal cells due to Multidrug Resistance (MDR) after the use of anticancer drugs. Proposed solution to overcome this problem is the use of MDR efflux inhibitor of cinchona alkaloids which is delivered together with anticancer drugs encapsulated in the form of polymeric nanoparticles. The particles were prepared by the hydration method. The characterization of nanoparticles was particle size, zeta potential, entrapment efficiency and in vitro drug release. Combination nanoparticle size ranged 29-45 nm with a neutral surface charge. Entrapment efficiency was above 87% for the use quinine, quinidine or cinchonidine in combination with etoposide. The release test results exhibited that the cinchona alkaloids release released faster than that of etoposide. Collectively, cinchona alkaloids can be packaged along with etoposide in nanomicelles for better cancer therapy.

Authors:

• Diky Mudhakir
• Satrialdi
• Sukmadjaja Asyarie
• Yeyet C. Sumirtapura

Keywords:

• Cinchona alkaloids
• etoposide
• MDR efflux inhitor
• polymeric nanomicelles.

References:

[1] World Health Organization Media Centre, http://www.who.int/
mediacentre/factsheets/fs297/en/
[2] M.R. Gwinn and V. Vallyathan, "Nanoparticles: Health effects-pros and
cons", Env. Health Perspect., vol. 114, no. 12, 2006, p. 1818-1825.
[3] K.T. Oh, H.J. Baik, A.H. Lee, Y.T. Oh, Y.S. Youn, and E.S. Lee, "The
reversal of drug-resistance in tumors using a drug-carrying nanoparticular
system", Int. J. Mol. Sci., vol. 10, no. 9, 2009, pp. 3776-3792.
[4] F.S. Liu, "Mechanisms of chemotherapeutic drug resistance in cancer
therapy-A quick review", Taiwan J. Obstet. Gynecol., vol. 48, no. 3, 2009,
pp. 239-242.
[5] W. Jager, "Classical resistance mechanisms", Int. J. of Clinical Pharm.
and Therapeutics, vol. 47, no. 1, 2009, pp. 46-48.
[6] M.M. Gottesman, T. Fojo, S.E. Bates,"Multidrug resistance in cancer:
Role of ATP-dependent transporters, Macmillan Magazines, vol 2, 2001,
pp. 48-58
[7] J.M. Lara S, L.E. van Vlerken, S. Yadaf and MM. Amiin,
"Multifunctional nanocarriers to overcome tumor drug resistance",
Cancer Treat. Rev., vol. 34, no. 7, 2008, pp. 592-602.
[8] W. Jun, Y. Lu, A. Lee, X. Pan, X. Yang , X. Zhao, and R.J. Lee, "Reversal
of multidrug resistance by transferrin-conjugated liposomes Co-en
capsulating doxorubicin and verapmil", J. Pharm. Pharmaceut. Sci, vol
10, no. 3, 2007, pp. 350-357.
[9] H.L. Wong, R.. Bedayan, A.M. Rauth, and X.Y. Wu, "Simultaneous
delivery of doxorubicin and GG918 by new polymer lipid hybrid
nanoparticle for enhanced treatment of multidrug resistant breast cancer",
J. Control. Rel., vol. 116, no. 3, 2006, pp. 275-284.
[10] P. Genne, D.B.M., Therese, Y.M. Roland, G. Gutierrez, O. Duchamp, J.M.
Petit, F. Martin, B. Chauffert, "Cinchonine, a potent efflux inhitor to
circumvent anthracycline resistance in vivo", AACR Journals, vol. 52, no.
10, 1992, pp. 2797-2801.
[11] S. Fusco, A. Borzacchiello, P.A. Netti, "Perspective on PEO-PPO-PEO
triblock copolymers and their biomedical applications", J. Bioact Compat
Pol., vol. 21, 2006, pp. 149-164.
[12] A. Kabanov E.V. Batrakove, VY. Alakhov, "Pluronic block copolymers
for overcoming drug resistance in cancer", Adv. Drug Deliv. Rev., vol. 54,
no. 5, 2002, pp. 759-779.
[13] N. Rapoport, G. Zhonggao, H.D. Fain, "Ultrasound-enhanced tumor
targeting of polymeric micellar drug carriers", Mol. Pharm., vol. 1, no. 4,
2004, pp. 317-330.
[14] E. Solary, L. Manone, D. Moreau, D. Caillot, R.O. Cassanov, H. Guy, M.
Grandjean, J.E. Wolf, F. Andre, P. Fenaux, P. Canal, B. Auffert, A.
Wotawa, M. Bayssas, P. Genne, "Phase I study of cinchonine, a multidrug
resistence reversing agent, combined with the CHVP regimen in relapsed
and refractory lymphoproliferatives syndromes", Leukemia, vol. 14 p.
2085-2094.